United Therapeutics (UTHR) Revenue (2016 - 2025)
Historic Revenue for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $799.5 million.
- United Therapeutics' Revenue rose 675.66% to $799.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 1129.99%. This contributed to the annual value of $2.9 billion for FY2024, which is 2362.62% up from last year.
- Latest data reveals that United Therapeutics reported Revenue of $799.5 million as of Q3 2025, which was up 675.66% from $798.6 million recorded in Q2 2025.
- United Therapeutics' Revenue's 5-year high stood at $799.5 million during Q3 2025, with a 5-year trough of -$7.9 million in Q4 2024.
- Moreover, its 5-year median value for Revenue was $506.9 million (2023), whereas its average is $519.0 million.
- Examining YoY changes over the last 5 years, United Therapeutics' Revenue showed a top increase of 3369.5% in 2024 and a maximum decrease of 89000.0% in 2024.
- Quarter analysis of 5 years shows United Therapeutics' Revenue stood at $415.2 million in 2021, then grew by 18.38% to $491.5 million in 2022, then plummeted by 99.8% to $1.0 million in 2023, then tumbled by 890.0% to -$7.9 million in 2024, then surged by 10220.25% to $799.5 million in 2025.
- Its Revenue stands at $799.5 million for Q3 2025, versus $798.6 million for Q2 2025 and $794.4 million for Q1 2025.